Antibody-targeted RNase fusion proteins (ImmunoRNases) for cancer therapy

被引：17

作者：

Krauss, Juergen ^{[1
]}

Arndt, Michaela A. E. ^{[1
]}

Duebel, Stefan ^{[2
]}

Rybak, Susanna M. ^{[3
]}

机构：

[1] Univ Heidelberg, Natl Ctr Tumor Dis NCT, D-69120 Heidelberg, Germany

[2] Tech Univ Carolo Wilhelmina Braunschweig, Dept Biotechnol, D-38106 Braunschweig, Germany

[3] Bionanomics LLC, Green Cove Springs, FL 32043 USA

来源：

CURRENT PHARMACEUTICAL BIOTECHNOLOGY | 2008年 / 9卷 / 03期

关键词：

RNase; Onconase (R); immunoRNase; antibody-RNase fusion protein; immunotherapeutics;

D O I：

10.2174/138920108784567317

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Ribonucleases (RNases) of the superfamily A exhibit potent antineoplastic activity yet do not mediate appreciable immunogenicity or non-specific toxicity in both animal models and cancer patients. Ranpirnase (Onconase (R)), the first ribonuclease being evaluated as a therapeutic in humans, has progressed to phase III clinical trials in patients with un-resectable mesothelioma. Conjugation of RNases to internalizing tumor-targeting monoclonal antibodies was shown to enhance specific cell killing by several orders of magnitude both in vitro and in animal models. In this review we describe the development and current status of genetically engineered 2(nd) generation immunoRNases as promising novel anticancer therapeutics.

引用

页码：231 / 234

页数：4

共 41 条

[1] A dimeric angiogenin immunofusion protein mediates selective toxicity towards CD22+ tumor cells [J].

Arndt, MAE ;

Krauss, J ;

Vu, BK ;

Newton, DL ;

Rybak, SM .

JOURNAL OF IMMUNOTHERAPY, 2005, 28 (03) :245-251

[2] Generation of a highly stable, internalizing anti-CD22 single-chain Fv fragment for targeting non-Hodgkin's lymphoma [J].

Arndt, MAE ;

Krauss, J ;

Schwarzenbacher, R ;

Vu, BK ;

Greene, S ;

Rybak, SM .

INTERNATIONAL JOURNAL OF CANCER, 2003, 107 (05) :822-829

[3] New anti-CD30 human pancreatic ribonuclease-based immunotoxin reveals strong and specific cytotoxicity in vivo [J].

Braschoss, Sandra ;

Hirsch, Burkhard ;

Duebel, Stefan ;

Stein, Harald ;

Duerkop, Horst .

LEUKEMIA & LYMPHOMA, 2007, 48 (06) :1179-1186

[4]

CAMPANA D, 1985, J IMMUNOL, V134, P1524

[5] Crystallographic and functional studies of a modified form of eosinophil-derive neurotoxin (EDN) with novel biological activities [J].

Chang, CS ;

Newton, DL ;

Rybak, SM ;

Wlodawer, A .

JOURNAL OF MOLECULAR BIOLOGY, 2002, 317 (01) :119-130

[6] A gender-specific mRNA encoding a cytotoxic ribonuclease contains a 3′ UTR of unusual length and structure [J].

Chen, SL ;

Le, SY ;

Newton, DL ;

Maizel, JV ;

Rybak, SM .

NUCLEIC ACIDS RESEARCH, 2000, 28 (12) :2375-2382

[7] SEMINAL RNASE - A UNIQUE MEMBER OF THE RIBONUCLEASE SUPERFAMILY [J].

DALESSIO, G ;

DIDONATO, A ;

PARENTE, A .

TRENDS IN BIOCHEMICAL SCIENCES, 1991, 16 (03) :104-106

[8]

De Lorenzo C, 2004, CANCER RES, V64, P4870

[9] Intracellular route and mechanism of action of ERB-hRNase, a human anti-ErbB2 anticancer immunoagent [J].

De Lorenzo, Claudia ;

Di Malta, Chiara ;

Cali, Gaetano ;

Troise, Fulvia ;

Nitsch, Lucio ;

D'Alessio, Giuseppe .

FEBS LETTERS, 2007, 581 (02) :296-300

[10] Design, characterization and anti-tumour cytotoxicity of a panel of recombinant, mammalian ribonuclease-based immunotoxins [J].

Deonarain, MP ;

Epenetos, AA .

BRITISH JOURNAL OF CANCER, 1998, 77 (04) :537-546

← 1 2 3 4 5 →